Dr. Kristi Funk, co-founder of the Pink Lotus Breast Center, and Dr. Paul Song, Chief Medical Officer at Cynvenio, discuss Triple Negative Breast Cancer monitoring.
Good Morning America: Dr. Kristi Funk, co-founder of the Pink Lotus Breast Center, discusses Cynvenio's new clinical research study for women with triple negative breast cancer (TNBC).
Cynvenio CEO, Andre' de Fusco, and Cynvenio CSO, Paul Dempsey, interviewed on CNBC's Mad Money.
Excerpts from Dr. Nimmi Kapoor's interview on ThisDay where she discusses genomics and breast cancer.
Excerpts from a talk by Dr. Kapoor, a surgical oncologist at Breastlink, presenting advances in screening, surveillance and the prevention of breast cancer recurrence.
Local ABC affiliate in Memphis, TN interviewing Cynvenio Clinical Advisory Board member, Dr. Lee Schwartzberg, about ClearID Breast Cancer.
The LiquidBiopsy™ instrument combined with the Ion Chef™ system and the Ion S5™ sequencers provide a seamless, end-to-end workflow for liquid biopsy cancer research. Learn how Cynvenio was able to scale up sample throughput using the Ion S5 sequencer.
Luca Quagliata, MD, of University Hospital, Basel, Switzerland discusses his use of the LiquidBiopsy platform and workflow in his research.
Liquid Biopsy in Immunotherapy and Beyond: Dr. Paul Song discusses the latest emerging developments in liquid biopsy technology which provide increased clinical utility particularly in the area of immunotherapy by highlighting several clinical case studies.
André de Fusco and Dr. Paul Dempsey (CEO and CSO of Cynvenio Biosystems Inc.) share their perspective on the need to simultaneously isolate cfDNA and circulating tumor cells (CTCs) from the same sample.
Dr. Strauss, Cynvenio's Director of Molecular Biology, discusses his work in using the Cynvenio Biosystems proprietary circulating tumor cell (CTC) isolation method, to develop a CTC DNA SNV sequencing platform.